1. Home
  2. TBPH

TBPH

Theravance Biopharma Inc.

Logo Theravance Biopharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Founded: N/A Country:
Cayman Islands
Cayman Islands
Employees: 99 City: GEORGE TOWN, GRAND CAYMAN
Market Cap: 470.5M IPO Year: N/A
Target Price: $20.50 AVG Volume (30 days): 362.7K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.00 EPS Growth: N/A
52 Week Low/High: $8.21 - $12.03 Next Earning Date: 05-06-2024
Revenue: $57,424,000 Revenue Growth: 11.84%
Revenue Growth (this year): 32.03% Revenue Growth (next year): 16.20%

Share on Social Networks: